Rosiglitazone (Molecule of the Month for May 2007)
Avandia, Avandamet, Avandaryl, rosiglitazone maleate
Rosiglitazone is an anti-diabetic drug from the thiazolidinedione class. It is being marketed as Avandia by the pharmaceutical company GlaxoSmithKline. Rosiglitazone acts primarily by increasing insulin sensitivity. Avandia is used in the management of type 2 diabetes mellitus. Rosiglitazone is an anti-diabetic drug from the thiazolidinedione class. Avandia improves glycemic control while reducing circulating insulin levels.
Pharmacological studies in animal models indicate that rosiglitazone improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis.
A February 2007 press release by GlaxoSmithKline notes a greater incidence of fractures of the upper arms, hands and feet in female diabetics given rosiglitazone compared with those given metformin or glyburide. In May 2007, an article in the New England Journal of Medicine tied the use of rosiglitazone to a 45% increased risk of heart attack.
Formal Chemical Name (IUPAC)
5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione
References
click on the picture of Rosiglitazone above to interact
with the 3D model of the
Rosiglitazone structure
(this will open a new browser window)
C18 H19 N3 O3 S
Update by Karl Harrison
(Molecule of the Month for
May 2007
)
All the images on this web site are are made available with a Creative Commons Attribution license and so can be used as long as the attribution © Karl Harrison 3DChem.com is written with the image. High resolution images and illustrations are available on request.